Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Consumer Sentiment Hits Record Low in May Amid Iran Conflict and Rising Oil Prices SpaceX and OpenAI MegaIPOs Raise Market Top Concerns Analysts Suggest Greenlanders Protest US Consulate Opening Amid Trumps Push for Island Control Phillies Former Pitcher Released by NL Contender After Brief ThreeGame Stint Payroll Implications for Contending Teams NIQ Global Intelligence CEO Buys 1 Million in Shares What It Could Signal Ready Capital Corporation RC Q1 2026 Earnings Deep EPS Miss as Net Loss Exceeds Expectations VTEX Q1 2026 Earnings EPS Miss Sends Shares Lower Amid Revenue Uncertainty Mineralys Therapeutics MLYS Q1 2026 Earnings Narrowerthanexpected Loss as Clinical Progress Continues VCEL Q1 2026 Earnings EPS Surprise of 241 Fails to Lift Shares LAC Q1 2026 Earnings NarrowerThanExpected Loss Highlights Progress on Thacker Pass Fidus Investment Corporation FDUS Shows Modest Gain Near Support Zone ACCO Stock Gains Ground Acco Brands Corporation Approaches Key Resistance at 401 ProCap Financial Warrants BRRWW Slide as Sentiment Weakens Near Key Support CCC Intelligent Solutions Holdings CCC Edges Higher as Shares Bounce from Support South Koreas Deputy PM Highlights Need for AI Wealth to Serve Public Good Amid Samsung Labor Unrest New York Fed Study Reveals Surging Gas Prices Hitting LowerIncome Households Harder Credit Suisse Economist Neelkanth Mishra Sees Scope for Meaningful Rate Cuts Repo Rate Could Hit Decade Low Latin American Leaders Champion Housing Finance and Climate Resilience at WUF13 RVTY Q1 2026 Earnings EPS Edges Past Estimates Revenue Details Not Disclosed HAFN Q4 2025 Earnings EPS Misses Estimates as Shares Slide 34 AbbVie ABBV Q1 2026 Earnings Slight EPS Beat Amid Steady Performance FNLC Q1 2026 Earnings EPS of 080 Reported Amid Quiet Quarter Voyager Therapeutics Q1 2026 Earnings EPS Beats Estimates as Stock Rises Amid Pipeline Progress Castle Biosciences Q1 2026 Earnings Narrowly Beats EPS Estimates but Stock Declines